RLMD (44) EBS (53) CYPH (40) GALT (42) ⌘ Pro Terminal →

ARS Pharmaceuticals Inc. (SPRY) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell SPRY stock right now?

ARS Pharmaceuticals Inc. (SPRY) currently earns a Roarable Rating of E (Strong Sell — SELL) with 27/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is SPRY's 12-month price target and RQD AI Jury consensus?

SPRY's 12-month base price target is $3.15 (range $2.46 to $13.81), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$3.66 +0.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ARS Pharmaceuticals Inc. (SPRY) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $364.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SPRY)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMOVERSOLD (<32)

29.830 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE3% OF RANGE

L: $3$3.66H: $13

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on SPRY

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (25)

Altman-Z 0.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like SPRY

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SPRY)

✓Walkthrough of SPRY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SPRY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.69%⚡ TESTING RESISTANCE

2026-10-30O $3.62H $3.79L $3.34C $3.66VOL 1.75M

RES: $3.75SUP: $2.39SMA50: $4.57SMA200: $7.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SPRY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SPRY Butterfly Map → + Track SPRY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SPRY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SPRY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SPRY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SPRY)

Health Care Rank #978 of 1016 ⚔️ RLMD vs SPRY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SPRY vs. RLMD, EBS, CYPH, GALT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ARS Pharmaceuticals Inc. (SPRY) ranks #978 by composite RQD confidence (27/100, grade E) and #496 by equity capitalization ($364.0M). Within this direct 5-issuer industry benchmark cohort, EBS leads on earnings valuation at 7.0x trailing P/E, while EBS leads on capital efficiency and profitability with 8.9% ROIC and 56.1% gross margin. EBS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with SPRY at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SPRY ACTIVE ARS Pharmaceuticals Inc.	E	27/100	—	—	-35.0%	+0.27%	$364.0M	Benchmark Subject
RLMD Relmada Therapeutics Inc.	D	44/100	—	—	-35.0%	+2.69%	$366.9M	/rlmd-vs-spry →
EBS Emergent BioSolutions Inc.	D+	53/100	7.0x	56.1%	8.9%	+1.83%	$370.2M	/ebs-vs-spry →
CYPH Cypherpunk Technologies Inc.	D-	40/100	71.3x	—	-23.3%	+2.16%	$356.7M	/cyph-vs-spry →
GALT Galectin Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.56%	$355.8M	/galt-vs-spry →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001671858

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ARS Pharmaceuticals Inc. (SPRY) reported GAAP revenue of $84.3M (-5.5% vs. FY2024 revenue of $89.1M , and +280826.7% cumulative change since FY2023) , GAAP net income of -$171.3M, operating cash flow of -$170.9M, and free cash flow of -$171.2M (-1418.5% YoY). On the balance sheet, SPRY closed FY2025 with $327.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$84.3M	-$171.3M	-$170.9M	-$171.2M	$327.7M	—
FY2024 (FY)	2024-12-31	$89.1M	$8.0M	$13.5M	$13.0M	$351.2M	—
FY2023 (FY)	2023-12-31	$30.0K	-$54.4M	-$59.3M	-$59.3M	—	—

3. SPRY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SPRY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $3.66 (+0.27% 1D, market cap $364.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SPRY ranks #978 in composite RQD confidence.

How does SPRY compare to RLMD and EBS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRY carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLMD (Relmada Therapeutics Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $366.9M) and EBS (Emergent BioSolutions Inc.) posts a D+ grade (53/100 RQD, P/E 7.0x, ROIC 8.9%, cap $370.2M). Among the 5-stock peer group, EBS leads on earnings multiple (7.0x) while EBS leads on capital efficiency (8.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SPRY?

Per SPRY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001671858), ARS Pharmaceuticals Inc. generated $84.3M in revenue (-5.5% YoY), -$171.3M in net income, and -$171.2M in free cash flow against $327.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SPRY trading relative to its 50-day, 200-day, and 52-week technical levels?

SPRY last traded at $3.66 (+0.27% on volume of 2,044,382 shares), positioning the stock -19.91% below its 50-day simple moving average ($4.57) and -50.47% below its 200-day simple moving average ($7.39). Across its 52-week range of $3.34 to $13.15, SPRY sits at the 3.3% percentile with a 14-day RSI of 29.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.20 to $4.12).

SPRY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SPRY stock right now?

ARS Pharmaceuticals Inc. (SPRY) currently earns a Roarable Rating of E (Strong Sell — SELL) with 27/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SPRY's 12-month price target and RQD AI Jury consensus?

SPRY's 12-month base price target is $3.15 (range $2.46 to $13.81), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SPRY RQD Cockpit SPRY 12M Forecast SPRY Earnings & Move SPRY Dividends & DRIP SPRY Insiders & 13F SPRY Whale Options SPRY Profit Sankey SPRY News & Why